By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


ChemoCentryx, Inc. 

850 Maude Avenue

Mountain View  California  94043  U.S.A.
Phone: 650-210-2900 Fax: 650-210-2910


ChemoCentryx is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics for autoimmune diseases, inflammatory disorders and cancer.

We have established one of the broadest pipelines of chemokine-based therapeutics in the biopharmaceutical industry based on our pioneering insight into the chemokine system, a complex network of chemokine (CHEMO-attractant cytoKINE) molecules (ligands) and receptors that work together to regulate inflammation.

ChemoCentryx has internally generated several clinical- and preclinical-stage compounds, each targeting distinct chemokine receptors and offering the potential to treat various diseases. ChemoCentryx's lead product candidate, Traficet-ENĀ®, or CCX282, is a first-in-class, anti-inflammatory small molecule therapeutic targeting the CCR9 chemokine receptor for the treatment of inflammatory bowel disease (IBD). We are currently conducting a definitive dose-ranging study designed to support the potential registration in induction of response or remission in Crohn's disease.

We have initiated a Phase I clinical trial of CCX915 which targets the chemokine receptor CCR2. The CCR2 receptor is of central importance to inflammatory diseases, such as multiple sclerosis, Type II diabetes and atherosclerosis. CCX915 is one of several clinical-quality molecules inhibiting this receptor that have been identified by ChemoCentryx.

Each of our novel small molecule product candidates is designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease while leaving the rest of the immune system intact. In addition, our orally-administered small molecules should offer convenience and compliance advantages, as well as lower costs of production over most biologic therapies.

ChemoCentryx is the only company focused exclusively on the discovery, development and commercialization of small molecule therapeutics that target the chemokine network. The company was founded by Thomas J. Schall, Ph.D., who participated in some of the earliest discoveries of chemokine system function and its activities. Since ChemoCentryx's founding, we have developed a set of proprietary drug discovery tools, known collectively as the EnabaLinkĀ® technology suite, specifically designed to unlock the chemokine system's complexity and to accelerate a productive drug discovery program. We have leveraged the EnabaLink drug discovery engine for the identification and optimization of each of our clinical and preclinical product candidates and we continue to apply these powerful research tools in our early-stage drug discovery efforts.

Key Management:

  • Thomas J. Schall, Ph.D., President and CEO
  • Markus J. Cappel, Ph.D., Senior Vice President, Corporate and Business Development
  • Susan M. Kanaya, Senior Vice President, Finance and Chief Financial Officer
  • J. J. (Kim) Wright, Ph.D., Senior Vice President, Medicinal Chemistry and Preclinical Development
  • Maureen Howard, Ph.D., Vice President of Research
  • Petrus (Pirow) Bekker, M.D., Ph.D., Vice President, Medical and Clinical Affairs

    Last Updated: 08-24-2006

    Key Statistics

    Ownership: Public

    Web Site: ChemoCentryx, Inc.
    Employees: 60
    Symbol: CCXI

  • Industry



    Company News
    ChemoCentryx, Inc. (CCXI) Reports Fourth Quarter 2014 Financial Results And Provides Corporate Update 3/13/2015 7:22:33 AM
    ChemoCentryx, Inc. (CCXI) To Hold Fourth Quarter 2014 Financial Results Conference Call On Thursday, March 12, 2015 2/26/2015 1:24:39 PM
    ChemoCentryx, Inc. (CCXI) To Present At The Cowen and Company 35th Annual Health Care Conference 2/17/2015 8:22:40 AM
    ChemoCentryx, Inc. (CCXI) To Present At The 33rd Annual J.P. Morgan Healthcare Conference 1/6/2015 10:18:55 AM
    ChemoCentryx, Inc. (CCXI)To Host Conference Call On Friday, December 12, 2014 To Discuss Top-Line Phase 2 Results In Patients With Diabetic Nephropathy With CCX140, An Orally Administered CCR2 Inhibitor 12/12/2014 7:24:10 AM
    ChemoCentryx, Inc. (CCXI) Announces Positive Results In Phase 2 Diabetic Nephropathy Trial With CCR2 Inhibitor CCX140 12/12/2014 6:58:09 AM
    ChemoCentryx, Inc. (CCXI) Granted EU Orphan Drug Designation For CCX168, An Orally Administered Complement C5a Receptor Inhibitor, For The Treatment Of Microscopic Polyangiitis And Granulomatosis With Polyangiitis, Two Forms Of ANCA-Associated Vasculitis 12/4/2014 4:39:56 PM
    ChemoCentryx, Inc. (CCXI)'s CCX168, An Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation In Atypical Hemolytic Uremic Syndrome Treatment By The FDA 11/21/2014 8:49:57 AM
    ChemoCentryx, Inc. (CCXI)'s Orally Administered C5aR Inhibitor CCX168 Shows Benefit In Non-Renal ANCA Vasculitis Disease Activity, In Addition To Previously Shown Kidney Disease Improvements 11/17/2014 2:51:09 PM
    ChemoCentryx, Inc. (CCXI) To Present At Two Upcoming Investor Conferences 11/6/2014 1:07:56 PM